Effect of Oral High Molecular Weight Hyaluronic Acid (HMWHA), Alpha Lipoic Acid (ALA), Magnesium, Vitamin B6 and Vitamin D Supplementation in Pregnant Women: A Retrospective Observational Pilot Study

Background—Pregnancy represents a nutritional challenge, since macro- and micronutrients intake can affect mother’ health and influence negative outcomes. The aim of this retrospective pilot study is to evidence whether the oral supplementation with high molecular weight hyaluronic acid (HMWHA), in...

Full description

Saved in:
Bibliographic Details
Published in:Clinics and practice 2023-09, Vol.13 (5), p.1123-1129
Main Authors: Parente, Eligio, Colannino, Giulia, Bilotta, Gabriele, Espinola, Maria Salomé Bezerra, Proietti, Sara, Oliva, Mario Montanino, Neri, Isabella, Aragona, Cesare, Unfer, Vittorio
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Autoimmune diseases
Blood diseases
Brief Report
Cytokines
Diabetes
Dietary supplements
Embryos
Hematoma
Hepatitis
high hyaluronic acid (HMWHA)
HIV
Human immunodeficiency virus
Human papillomavirus
Hypertension
Magnesium
Miscarriage
Molecular weight
oral treatment
Physiology
Pilot projects
Placental abruption
Preeclampsia
Pregnancy
pregnant women
Premature birth
prevention of adverse events
Thyroid gland
Vitamin D
Vitamin deficiency
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background—Pregnancy represents a nutritional challenge, since macro- and micronutrients intake can affect mother’ health and influence negative outcomes. The aim of this retrospective pilot study is to evidence whether the oral supplementation with high molecular weight hyaluronic acid (HMWHA), in association with alpha lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, in pregnant women, could reduce adverse effects, such as PTB, pelvic pain, contraction and hospitalization. Methods—Data were collected from n = 200 women treated daily with oral supplements of 200 mg HMWHA, 100 mg ALA, 450 mg magnesium, 2.6 mg vitamin B6 and 50 mcg vitamin D (treatment group) and from n = 50 women taking with oral supplements of 400 mg magnesium (control group). In both groups, supplementation started from the 7th gestational week until delivery. Results—Oral treatment with HMWHA, in association with ALA, magnesium, vitamin B6 and vitamin D in pregnant women, significantly reduced adverse events, such as PTB (p < 0.01), pelvic pain and contractions (p < 0.0001), miscarriages (p < 0.05) and admission to ER/hospitalization (p < 0.0001) compared with the control group. Conclusions—Despite HMWHA having been poorly used as a food supplement in pregnant women, our results open a reassuring scenario regarding its oral administration during pregnancy.
ISSN:2039-7283
2039-7275
2039-7283
DOI:10.3390/clinpract13050100